{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:24:51Z","timestamp":1793838291280,"version":"4.6.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:00:00Z","timestamp":1793836800000},"content-version":"vor","delay-in-days":115,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100010638","name":"Huntsman Cancer Institute","doi-asserted-by":"publisher","award":["P30 CS042014"],"award-info":[{"award-number":["P30 CS042014"]}],"id":[{"id":"10.13039\/100010638","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Utah's Therapeutics Accelerator"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-026-10602-4","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:26:18Z","timestamp":1783945578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Computer-guided dosing of multi-specific T-cell engagers"],"prefix":"10.1038","volume":"9","author":[{"given":"Isaac","family":"Kendell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"McShinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Modzelewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Naatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bearss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffry","family":"Troll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-2698","authenticated-orcid":false,"given":"Douglas","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5996-7679","authenticated-orcid":false,"given":"Shawn","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0461-4926","authenticated-orcid":false,"given":"M. Tommy","family":"Gambles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"10602_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.csbj.2024.12.030","volume":"27","author":"Y Wu","year":"2025","unstructured":"Wu, Y. & Xie, L. AI-driven multi-omics integration for multi-scale predictive modeling of genotype-environment-phenotype relationships. Comput. Struct. Biotechnol. J. 27, 265\u2013277 (2025).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10602_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev-biodatasci-102523-103801","volume":"7","author":"Y Nam","year":"2024","unstructured":"Nam, Y. et al. Harnessing artificial intelligence in multimodal omics data integration: paving the path for the next frontier in precision medicine. Annu. Rev. Biomed. Data Sci. 7, 225\u2013250 (2024).","journal-title":"Annu. Rev. Biomed. Data Sci."},{"key":"10602_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1146\/annurev-bioeng-081623-025834","volume":"26","author":"G Lorenzo","year":"2024","unstructured":"Lorenzo, G. et al. Patient-specific, mechanistic models of tumor growth incorporating artificial intelligence and big data. Annu. Rev. Biomed. Eng. 26, 529\u2013560 (2024).","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10602_CR4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41586-024-08378-w","volume":"638","author":"J Xiang","year":"2025","unstructured":"Xiang, J. et al. A vision-language foundation model for precision oncology. Nature 638, 769\u2013778 (2025).","journal-title":"Nature"},{"key":"10602_CR5","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1182\/blood.2024025454","volume":"145","author":"LH Sehn","year":"2025","unstructured":"Sehn, L. H. et al. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies. Blood 145, 708\u2013719 (2025).","journal-title":"Blood"},{"key":"10602_CR6","doi-asserted-by":"crossref","unstructured":"Negishi, S. et al. Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma. Front. Pediatr. 11, 1305657 (2024).","DOI":"10.3389\/fped.2023.1305657"},{"key":"10602_CR7","doi-asserted-by":"publisher","first-page":"23341","DOI":"10.1021\/acsnano.4c06500","volume":"18","author":"MT Gambles","year":"2024","unstructured":"Gambles, M. T. et al. Multiantigen T-cell hybridizers: a two-component T-cell activating therapy. ACS Nano 18, 23341\u201323352 (2024).","journal-title":"ACS Nano"},{"key":"10602_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2025.102825","volume":"67","author":"MT Gambles","year":"2025","unstructured":"Gambles, M. T. et al. Two-component T-cell immunotherapy enables antigen pre-targeting to reduce cytokine release without forfeiting efficacy. Nanomed. Nanotechnol. Biol. Med. 67, 102825 (2025).","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10602_CR9","doi-asserted-by":"crossref","unstructured":"Li, S. et al. Self-assembling multi-antigen T-cell hybridizers for precision immunotherapy of multiple myeloma. Adv. Healthcare Mater. 14, e02156 (2025).","DOI":"10.1002\/adhm.202502156"},{"key":"10602_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00997-w","volume":"14","author":"A Trabolsi","year":"2024","unstructured":"Trabolsi, A., Arumov, A. & Schatz, J. H. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood Cancer J. 14, 27 (2024).","journal-title":"Blood Cancer J."},{"key":"10602_CR11","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1111\/jcmm.17930","volume":"27","author":"Q Liu","year":"2023","unstructured":"Liu, Q. et al. Prolonged haematologic toxicity in CAR-T cell therapy: a review. J. Cell. Mol. Med. 27, 3662\u20133671 (2023).","journal-title":"J. Cell. Mol. Med."},{"key":"10602_CR12","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1182\/blood.2023022432","volume":"143","author":"JL Crombie","year":"2024","unstructured":"Crombie, J. L. et al. Consensus recommendations of the management of toxicity associated with CD3xCD20 bispecific antibody therapy. Blood 143, 1565\u20131575 (2024).","journal-title":"Blood"},{"key":"10602_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","volume":"22","author":"NE Scharping","year":"2021","unstructured":"Scharping, N. E. et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T-cell exhaustion. Nat. Immunol. 22, 205\u2013215 (2021).","journal-title":"Nat. Immunol."},{"key":"10602_CR14","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41573-022-00501-8","volume":"21","author":"SC Oostindie","year":"2022","unstructured":"Oostindie, S. C., Lazar, G. A., Schuurman, J. & Parren, P. W. H. I. Avidity in antibody effector functions and biotherapeutic drug design. Nat. Rev. Drug Discov. 21, 715\u2013735 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"10602_CR15","doi-asserted-by":"publisher","unstructured":"Frey, N. C. et al. Lab-in-the-loop therapeutic antibody design with deep learning. bioRxiv p. 2025.02.19.639050. https:\/\/doi.org\/10.1101\/2025.02.19.639050 (2025).","DOI":"10.1101\/2025.02.19.639050"},{"key":"10602_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1001\/jamaoncol.2023.4504","volume":"10","author":"M Ventin","year":"2024","unstructured":"Ventin, M. et al. Implications of high tumor burden on chimeric antigen receptor T-cell immunotherapy: a review. JAMA Oncol. 10, 115\u2013121 (2024).","journal-title":"JAMA Oncol."},{"key":"10602_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40364-022-00378-0","volume":"10","author":"K Sankar","year":"2022","unstructured":"Sankar, K. et al. The role of biomarkers in personalized immunotherapy. Biomark. Res. 10, 32 (2022).","journal-title":"Biomark. Res."},{"key":"10602_CR18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejca.2022.05.008","volume":"171","author":"M Mallet","year":"2022","unstructured":"Mallet, M. et al. Tumour burden and antigen-specific T-cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T-cell therapy. Eur. J. Cancer 171, 96\u201315 (2022).","journal-title":"Eur. J. Cancer"},{"key":"10602_CR19","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/s41551-019-0436-x","volume":"3","author":"L Scheetz","year":"2019","unstructured":"Scheetz, L. et al. Engineering patient-specific cancer immunotherapies. Nat. Biomed. Eng. 3, 768\u2013782 (2019).","journal-title":"Nat. Biomed. Eng."},{"key":"10602_CR20","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41416-021-01413-x","volume":"125","author":"C Pilard","year":"2021","unstructured":"Pilard, C. et al. Cancer immunotherapy: it\u2019s time to better predict patients\u2019 response. Br. J. Cancer 125, 927\u2013938 (2021).","journal-title":"Br. J. Cancer"},{"key":"10602_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/cpt.1942","volume":"108","author":"Z Agur","year":"2020","unstructured":"Agur, Z., Elishmereni, M., Fory\u015b, U. & Kogan, Y. Accelerating the development of personalized cancer immunotherapy by integrating molecular patients\u2019 profiles with dynamic mathematical models. Clin. Pharmacol. Ther. 108, 515\u2013527 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"key":"10602_CR22","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.3324\/haematol.2018.207266","volume":"104","author":"SC Oostindie","year":"2019","unstructured":"Oostindie, S. C. et al. CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering. Haematologica 104, 1841\u20131852 (2019).","journal-title":"Haematologica"},{"key":"10602_CR23","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jconrel.2022.08.045","volume":"350","author":"MT Gambles","year":"2022","unstructured":"Gambles, M. T. et al. Simultaneous crosslinking of CD20 and CD38 receptors by drug-free macromolecular therapeutics enhances B-cell apoptosis in vitro and in vivo. J. Control. Release 350, 584\u2013599 (2022).","journal-title":"J. Control. Release"},{"key":"10602_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201706098","volume":"30","author":"Y Mi","year":"2018","unstructured":"Mi, Y. et al. A dual immunotherapy nanoparticle improves T-cell activation and cancer immunotherapy. Adv. Mater. 30, 1706098 (2018).","journal-title":"Adv. Mater."},{"key":"10602_CR25","first-page":"228","volume":"4","author":"W Cai","year":"2021","unstructured":"Cai, W. et al. Biological activity validation of a computationally designed rituximab\/CD3 T-cell engager targeting CD20+ cancers with multiple mechanisms of action. Antib. Ther. 4, 228\u2013241 (2021).","journal-title":"Antib. Ther."},{"key":"10602_CR26","doi-asserted-by":"publisher","first-page":"11422","DOI":"10.1021\/acsnano.9b04868","volume":"13","author":"L Li","year":"2019","unstructured":"Li, L. et al. Broadening and enhancing functions of antibodies by self-assembling multimerization at cell surface. ACS Nano 13, 11422\u201311432 (2019).","journal-title":"ACS Nano"},{"key":"10602_CR27","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1021\/acsnano.8b00797","volume":"12","author":"L Li","year":"2018","unstructured":"Li, L., Yang, J., Wang, J. & Kope\u010dek, J. Amplification of CD20 cross-linking in rituximab-resistant B lymphoma cells enhances apoptosis induction by drug-free macromolecular therapeutics. ACS Nano 12, 3658\u20133670 (2018).","journal-title":"ACS Nano"},{"key":"10602_CR28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","volume":"16","author":"A Tapia-Galisteo","year":"2023","unstructured":"Tapia-Galisteo, A., \u00c1lvarez-Vallina, L. & Sanz, L. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. J. Hematol. Oncol. 16, 83 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"10602_CR29","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"T-C Chou","year":"2010","unstructured":"Chou, T.-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440\u2013446 (2010).","journal-title":"Cancer Res."},{"key":"10602_CR30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejca.2022.05.008","volume":"171","author":"M Mallet","year":"2022","unstructured":"Mallet, M. et al. Tumor burden and antigen-specific T-cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell therapy. Eur. J. Cancer 171, 96\u2013105 (2022). 4.","journal-title":"Eur. J. Cancer"},{"key":"10602_CR31","doi-asserted-by":"publisher","first-page":"5813","DOI":"10.1182\/blood.V124.21.5813.5813","volume":"124","author":"A Dolnikov","year":"2014","unstructured":"Dolnikov, A. et al. Identifying the factors modulating the efficacy of CAR-T cell therapy. Blood 124, 5813 (2014).","journal-title":"Blood"},{"key":"10602_CR32","doi-asserted-by":"crossref","unstructured":"Ball, K., Dovedi, S. J., Vajjah, P. & Phipps, A. Strategies for clinical dose optimization of T-cell engaging therapies in oncology. mAbs 15, 2181016 (2023).","DOI":"10.1080\/19420862.2023.2181016"},{"key":"10602_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4049\/immunohorizons.2200092","volume":"7","author":"MR McCaleb","year":"2023","unstructured":"McCaleb, M. R., Miranda, A. M., Ratliff, K. C., Torres, R. M. & Pelanda, R. CD19 is internalized together with IgM in proportion to B cell receptor stimulation and is modulated by phosphatidylinositol 3-kinase in bone marrow immature B cells. ImmunoHorizons 7, 49\u201363 (2023).","journal-title":"ImmunoHorizons"},{"key":"10602_CR34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2967\/jnumed.122.263962","volume":"64","author":"GT Havlena","year":"2023","unstructured":"Havlena, G. T. et al. Cure of micrometastatic B-cell lymphoma in a s SCID mouse model using 213Bi-anti-CD20 monoclonal antibody. J. Nucl. Med. 64, 109\u2013116 (2023).","journal-title":"J. Nucl. Med."},{"key":"10602_CR35","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/s43018-024-00772-7","volume":"5","author":"T-G Chang","year":"2024","unstructured":"Chang, T.-G. et al. LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and gnomic features. Nat. Cancer 5, 1158\u20131175 (2024).","journal-title":"Nat. Cancer"},{"key":"10602_CR36","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/s43018-024-00756-7","volume":"5","author":"S Sinha","year":"2024","unstructured":"Sinha, S. et al. PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors. Nat. Cancer 5, 938\u2013952 (2024).","journal-title":"Nat. Cancer"},{"key":"10602_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-024-05723-8","volume":"25","author":"C Lao","year":"2024","unstructured":"Lao, C. et al. DeepAEG: a model for predicting cancer drug response based on data enhancement and edge-collaborative update strategies. BMC Bioinforma. 25, 105 (2024).","journal-title":"BMC Bioinforma."},{"key":"10602_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-04296-3","volume":"12","author":"M Li","year":"2022","unstructured":"Li, M. et al. The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r\/r B-ALL patients. Sci. Rep. 12, 378 (2022).","journal-title":"Sci. Rep."},{"key":"10602_CR39","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CPM Verkleij","year":"2021","unstructured":"Verkleij, C. P. M. et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 5, 2196\u20132215 (2021).","journal-title":"Blood Adv."},{"key":"10602_CR40","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jconrel.2023.04.048","volume":"358","author":"MT Gambles","year":"2023","unstructured":"Gambles, M. T., Yang, J. & Kope\u010dek, J. Multi-targeted immunotherapeutics to treat B-cell malignancies. J. Control Release 358, 232\u2013258 (2023).","journal-title":"J. Control Release"},{"key":"10602_CR41","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1146\/annurev-med-042921-024719","volume":"74","author":"F Furqan","year":"2023","unstructured":"Furqan, F. & Shah, N. N. Multispecific CAR T cells deprive lymphomas of escape via antigen loss. Annu. Rev. Med. 74, 279\u2013291 (2023).","journal-title":"Annu. Rev. Med."},{"key":"10602_CR42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-018-0629-x","volume":"11","author":"D Kasakovski","year":"2018","unstructured":"Kasakovski, D., Xu, L. & Li, Y. T cell senescence and CAR-T cell exhaustion in hematological malignancies. J. Hematol. Oncol. 11, 91 (2018).","journal-title":"J. Hematol. Oncol."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10602-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10602-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10602-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:32:20Z","timestamp":1793835140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10602-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10602"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-10602-4","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.T.G. is a co-inventor on a pending US patent application (AI Modeling Using Multi-Antigen T-Cell Hybridizers (MATCH)) related to this work; it is assigned to the University of Utah. M.T.G. and I.K. hold shares in a corporation that is in conversation to license the relevant IP from the University of Utah. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"1467"}}